Cargando…

Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020

The persistence of immunity after hepatitis B vaccination is still under investigation in adults. In Chaoyang District, Beijing, people who were aged ≥ 18 years and completely immunized with HBV vaccine according to the standard procedure (0–1–6 months) were enrolled. Three groups were set for 1 (Y1...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Sijia, Ge, Shen, Zhang, Zheng, Ma, Jianxin, Jiao, Yang, Li, Qian, Liang, Yan, Li, Shuming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877256/
https://www.ncbi.nlm.nih.gov/pubmed/35214640
http://dx.doi.org/10.3390/vaccines10020181
_version_ 1784658377212690432
author Shen, Sijia
Ge, Shen
Zhang, Zheng
Ma, Jianxin
Jiao, Yang
Li, Qian
Liang, Yan
Li, Shuming
author_facet Shen, Sijia
Ge, Shen
Zhang, Zheng
Ma, Jianxin
Jiao, Yang
Li, Qian
Liang, Yan
Li, Shuming
author_sort Shen, Sijia
collection PubMed
description The persistence of immunity after hepatitis B vaccination is still under investigation in adults. In Chaoyang District, Beijing, people who were aged ≥ 18 years and completely immunized with HBV vaccine according to the standard procedure (0–1–6 months) were enrolled. Three groups were set for 1 (Y1), 5 (Y5) and 10 (Y10) years after the hepatitis B vaccination. The following data was collected and analyzed: antibody against hepatitis B virus surface antigen(anti-HBs) positive rates and geometric mean concentration (GMC) between the different compared groups through questionnaires and laboratory detection, including hepatitis B virus surface antigen (HBsAg), anti-HBs and antibody against hepatitis B virus core antigen(anti-HBc). All 600 subjects completed the questionnaires and serological tests. Among all subjects, the positive rates of HBsAg, anti-HBs and anti-HBc were 0, 70.5% (423/600) and 2.5% (15/600), respectively. The anti-HBs positive rates in Y1, Y5 and Y10 groups were 86.5% (173/200), 71.0% (142/200) and 54.0% (108/200) (χ(2) = 50.8, p < 0.001) and showed a linear decreasing trend year by year (trend χ(2) = 50.7, p < 0.001). The GMC in Y1, Y5 and Y10 groups were 296.6 mIU/mL, 51.6 mIU/mL and 25.5 mIU/mL (H = 64.8, p < 0.001), respectively. The anti-HBs positive rates and GMC decreased rapidly after the vaccination of adults against hepatitis B. Screening after 5–10 years and booster vaccination for the unprotected population is recommended.
format Online
Article
Text
id pubmed-8877256
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88772562022-02-26 Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020 Shen, Sijia Ge, Shen Zhang, Zheng Ma, Jianxin Jiao, Yang Li, Qian Liang, Yan Li, Shuming Vaccines (Basel) Article The persistence of immunity after hepatitis B vaccination is still under investigation in adults. In Chaoyang District, Beijing, people who were aged ≥ 18 years and completely immunized with HBV vaccine according to the standard procedure (0–1–6 months) were enrolled. Three groups were set for 1 (Y1), 5 (Y5) and 10 (Y10) years after the hepatitis B vaccination. The following data was collected and analyzed: antibody against hepatitis B virus surface antigen(anti-HBs) positive rates and geometric mean concentration (GMC) between the different compared groups through questionnaires and laboratory detection, including hepatitis B virus surface antigen (HBsAg), anti-HBs and antibody against hepatitis B virus core antigen(anti-HBc). All 600 subjects completed the questionnaires and serological tests. Among all subjects, the positive rates of HBsAg, anti-HBs and anti-HBc were 0, 70.5% (423/600) and 2.5% (15/600), respectively. The anti-HBs positive rates in Y1, Y5 and Y10 groups were 86.5% (173/200), 71.0% (142/200) and 54.0% (108/200) (χ(2) = 50.8, p < 0.001) and showed a linear decreasing trend year by year (trend χ(2) = 50.7, p < 0.001). The GMC in Y1, Y5 and Y10 groups were 296.6 mIU/mL, 51.6 mIU/mL and 25.5 mIU/mL (H = 64.8, p < 0.001), respectively. The anti-HBs positive rates and GMC decreased rapidly after the vaccination of adults against hepatitis B. Screening after 5–10 years and booster vaccination for the unprotected population is recommended. MDPI 2022-01-25 /pmc/articles/PMC8877256/ /pubmed/35214640 http://dx.doi.org/10.3390/vaccines10020181 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shen, Sijia
Ge, Shen
Zhang, Zheng
Ma, Jianxin
Jiao, Yang
Li, Qian
Liang, Yan
Li, Shuming
Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020
title Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020
title_full Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020
title_fullStr Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020
title_full_unstemmed Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020
title_short Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020
title_sort persistence of immunity in adults after 1, 5 and 10 years with recombinant hepatitis b vaccine in beijing in 2010–2020
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877256/
https://www.ncbi.nlm.nih.gov/pubmed/35214640
http://dx.doi.org/10.3390/vaccines10020181
work_keys_str_mv AT shensijia persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020
AT geshen persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020
AT zhangzheng persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020
AT majianxin persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020
AT jiaoyang persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020
AT liqian persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020
AT liangyan persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020
AT lishuming persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020